Cellnovo to Market its Diabetes Management System in Italy
11 February 2016 - 05:00PM
Business Wire
Regulatory News:
Cellnovo Group (Paris:CLNV) (“Cellnovo” CLNV:EN Paris), a
medical technology company marketing the first connected all-in-one
diabetes management system, today announces it has completed the
full registration process required by the Italian Ministry of
Health for medical devices and is now able to import and distribute
the Cellnovo diabetes management system in Italy.
There are estimated to be more than 300,000 Type 1 diabetes
patients in Italy.1 The launch in this market marks an important
further step in Cellnovo’s European commercialisation strategy. The
launch also follows the recent announcement of first sales in The
Netherlands and increasing sales in France and the UK.
In support of successful commercialisation in Italy and
continuing to raise the profile of Cellnovo’s technology
internationally, the Company was also present at the Advanced
Technologies & Treatments for Diabetes (ATTD) conference in
Milan from 3rd to 6th February. ATTD is the biggest European
meeting covering technology for diabetes and brings together
clinicians and thought leaders from more than 90 countries.
Sophie Baratte, CEO of Cellnovo, commented: “We are
pleased to see the Italian market open for our unique diabetes
management system. This is another key milestone in building out
our commercial platform ahead of our anticipated scale up in
manufacturing capacity in H2 2016 as Flex (Flextronics) comes fully
on line.
“During ATTD, we saw a lot of traction on our booth with many
clinicians, among them Italians, expressing interest in the
wearability of our innovative patch pump and the potential the
Cellnovo system offers by its e-connectivity. We look forward to
making our technology available to Italian patients.”
1Association of Diabetes in Italy
(http://www.aemmedi.it/)
------
About Cellnovo (Euronext: CLNV)An international
commercial medical technology company, Cellnovo markets the first
mobile, connected all-in-one diabetes management system, a
disruptive technology enhancing daily disease management for Type 1
diabetes patients. Cellnovo’s device currently addresses the $2.2
billion insulin pump market and the Company is reviewing the
potential for the device to serve other markets. Cellnovo is
currently marketing the device in the UK, France and The
Netherlands and has a clearly defined commercial and manufacturing
strategy supported by strategic partners Air Liquide and
Flextronics. Cellnovo is headquartered in Paris France with product
development facilities in Wales, UK. For further information please
visit www.cellnovo.com
About the Cellnovo Diabetes Management SystemCompact,
tubeless, intuitive and entirely connected, Cellnovo’s insulin pump
comprises a mobile touchscreen controller with an integrated
blood-glucose meter. This unique device allows optimal management
of insulin injections with drop-by-drop precision, whilst ensuring
extensive freedom of movement and peace of mind for patients.
Thanks to the automatic transmission of data, it also allows the
patient’s condition to be continually monitored by family members
and healthcare professionals in real-time.
Cellnovo is listed on Euronext, Compartment C
ISIN: FR0012633360 – Ticker: CLNV
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160210006277/en/
CellnovoChief Executive OfficerSophie
Baratteinvestors@cellnovo.comorNewCapInvestor
RelationsEmmanuel Huynh, + 33 1 44 71 00 16Media Relations in
FranceNicolas Merigeau, + 33 1 44 71 94
98cellnovo@newcap.euorConsilium Strategic
CommunicationsMedia Relations in United KingdomAmber Fennell,
Chris Gardner, Chris Welsh, Laura Thornton, +44 20 3709
5700cellnovo@consilium.com